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Abstract
Colon cancer metastasis is often associated with activation of the Wnt/β-catenin signaling pathway and high expres-
sion of the metastasis mediator S100A4. We previously demonstrated the transcriptional regulation of S100A4 by
β-catenin and the importance of the interconnection of these cellular programs for metastasis. Here we probe the
hypothesis that the nonsteroidal anti-inflammatory drug sulindac sulfide can inhibit colon cancer metastasis by inter-
vening in β-catenin signaling and thereby interdicting S100A4. We treated colon cancer cell lines heterozygous for
gain-of-function and wild-type β-catenin with sulindac. We analyzed sulindac’s effects on β-catenin expression and
subcellular localization, β-catenin binding to the T-cell factor (TCF)/S100A4 promoter complex, S100A4 promoter activ-
ity, S100A4 expression, cell motility, and proliferation. Mice intrasplenically transplanted with S100A4-overexpressing
colon cancer cells were treated with sulindac. Tumor growth and metastasis, and their β-catenin and S100A4 expres-
sions, were determined. We report the expression knockdown of β-catenin by sulindac, leading to its reduced nuclear
accumulation. The binding of β-catenin to TCF was clearly lowered, resulting in reduced S100A4 promoter activity and
expression. This correlated well with the inhibition of cell migration and invasion, which could be rescued by ectopic
S100A4 expression. In mice, sulindac treatment resulted in reduced tumor growth in the spleen (P = .014) and de-
creased liver metastasis in a human colon cancer xenograft model (P = .025). Splenic tumors and liver metastases
of sulindac-treated mice showed lowered β-catenin and S100A4 levels. These results suggest that modulators of
β-catenin signaling such as sulindac offer potential as antimetastatic agents by interdicting S100A4 expression.
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Introduction
Colon cancer is the second most frequent malignancy in the Western
world and represents one of the leading causes of cancer-related deaths.
The 5-year survival rates are approximately 90% for early stage patients,
dropping to 65% in patients with regional lymph node metastases and
decreasing to less than 10% in patients with distant metastases [1]. The
metastatic dissemination of primary tumors is directly linked to pa-
tient survival and accounts for approximately 90% of all colon cancer
deaths [2]. Distant metastases develop in approximately 50% of all co-
lon cancer patients, preferentially in the liver [3]. Half of these patients
develop distant metastases after initial surgery of their primary tumor
(metachronous metastasis). However, therapeutic options are limited,
particularly for patients with metastases. Patients at high risk for metas-
tasis, ideally identified well before the occurrence of metastasis, would
benefit most from antimetastatic therapies [4].
The metastasis mediator, S100A4, a member of the S100 family of
calcium-binding proteins, provides a marker for the early identification
of patients at high risk for distant metastasis. S100A4 is overexpressed
in many different types of cancer and has negative significance for prog-
nosis and patient survival [5–7]. In colorectal cancer, S100A4 levels and
nuclear localization increase during tumor progression [8–11]. High
S100A4 levels in colorectal tumors are associated with aggressive
growth, metastasis, poor prognosis, and shortened patient survival
times [12–14]. We previously demonstrated a significant positive cor-
relation of S100A4 levels in primary tumors with subsequent metastasis
and patient survival [15].
More than 90% of colorectal cancers bear mutations that result
in Wnt pathway activation [16,17]. These mutations generally affect
β-catenin phosphorylation, hindering its degradation through the ubi-
quitin pathway. Nonphosphorylated β-catenin accumulates in the cyto-
plasm, enters the nucleus, and interacts with T-cell factor (TCF)
transcription factors to control target genes. Nuclear β-catenin accumu-
lation has been correlated with late stages of tumor progression and
metastasis; the presence of mutated β-catenin is associated with ag-
gressive tumor growth and poor prognosis [18,19]. We previously
demonstrated the dependence of β-catenin–induced migration and
invasiveness on S100A4. We identified S100A4 as a transcriptional β-
catenin target gene. Transplantation of colon cancer cells with gain-of-
function β-catenin and high S100A4 expression resulted in distant
metastasis in mice [15].
Here we probed the functional significance of our findings using
the nonsteroidal anti-inflammatory drug (NSAID) sulindac sulfide
(sulindac), a known pharmacological inhibitor of β-catenin, for preven-
tion of metastasis. Sulindac inhibits β-catenin expression in colorectal
cancer cells and in patients with hereditary nonpolyposis colorectal
cancer and familial adenomatous polyposis [20–22]. Sulindac induces
proteasome-dependent degradation of β-catenin and suppresses tumori-
genesis in vivo by downregulating β-catenin signaling [23,24]. It inhibits
the nuclear accumulation of β-catenin in colorectal carcinoma cell lines
and in adenomas of patients with familial adenomatous polyposis lead-
ing to reduced downstream signaling [25]. Consequently, β-catenin
target genes like Met, c-myc, and cyclin D1 are downregulated after su-
lindac treatment [22,25–28].
We studied the effects of sulindac on the expression and subcellular
localization of β-catenin and on the expression and promoter activity
of its transcriptional target gene S100A4. We evaluated the effect of
sulindac on functional parameters such as cell migration, invasiveness,
and proliferation of human colon cancer cells in the context of S100A4
expression inhibition. For preclinical evaluation, we identified sulindac
concentrations that are nontoxic but effective for metastasis prevention
in mice. Finally, we demonstrate that the antimetastatic potential of
sulindac in mice is closely coupled to the intervention in β-catenin sig-
naling and interdicting S100A4 expression.
Materials and Methods
Tumor Cell Lines, Transfections, and Treatments
HCT116 cells (heterozygous for β-catenin wild-type/Δ45 exon 3)
and the β-catenin knockout sublines were kindly obtained from Todd
Waldman, Georgetown University, Washington, DC [29]. HAB-68mut
cells express only the Δ45 mutant (mut) allele, and HAB-92wt cells
express only one wild-type (wt) allele of β-catenin. Sublines with recon-
stituted heterozygous genotype, HAB-68mut/wt and HAB-92wt/mut,
were generated by stable transfection with wt β-catenin complementary
DNA (cDNA) into HAB-68mut and Δ45-gain-of-function β-catenin
cDNA into HAB-92wt cells. β-Catenin genotypes were confirmed by
sequencing exon 3 and by reverse transcription–polymerase chain re-
action (RT-PCR)–based restriction fragment length polymorphism
[15]. Transfections of wt and Δ45-mutant β-catenin cDNA (kindly
provided by Bert Vogelstein, Johns Hopkins University, Baltimore,
MD [30]) of S100A4 cDNA (kindly provided by Claus Heizmann,
University of Zurich, Switzerland [31]), of c-myc cDNA (cloned
in our laboratory), and of cyclin D1 cDNA (kindly provided by Klaus
Wethmar, Max-Delbrück-Center for Molecular Medicine, Berlin,
Germany) were performed using lipofectin (Invitrogen, Karlsruhe,
Germany). For each transfection experiment, at least three independent
transfected clones were analyzed; one representative clone thereof
is shown, respectively. Cells were grown in RPMI 1640 (HCT116
cells and sublines, SW620) or Dulbecco modified Eagle medium
(LS174TandDLD1) supplementedwith 10% fetal calf serum. Sulindac
treatment in vitrowas performed with 100 μM sulindac sulfide (Sigma,
Munich, Germany [25]) for 24 hours (RT-PCR, reporter expression,
migration, and invasion), 48 hours (β-catenin immunocytochemistry
and Western blot analysis), 4 days (wound healing), 5 days (prolifera-
tion), and 10 days (colony formation).
Quantitative Real-time RT-PCR
Quantitative real-time RT-PCR was performed in parallel and in
duplicate per sample, as described previously [15]. For β-catenin and
S100A4, amplicons of 152 and 124 bp were produced, respectively.
The following primers and probes were used: β-catenin, forward primer
5′-gtgctatctgtctgctctagta-3′, reverse primer 5′-cttcctgtttagttgcagcatc-3′,
FITC probe 5′-aggacttcacctgacagatccaagtca-3′, LCRed640 probe 5′-
cgtcttgttcagaactgtctttggactctc-3′; S100A4, forward primer 5′-gagctgcc-
cagcttcttg-3′, reverse primer 5′-tgcaggacaggaagacacag-3′, FITC probe
5′-tgatgagcaacttggacagcaaca-3′, LCRed640 probe 5′-gacaacgaggtggacttc-
caagagt-3′ (BioTeZ and TIB MolBiol, Berlin, Germany). Messenger
RNA (mRNA) expressions of c-myc and cyclin D1 were determined
by SYBR green RT-PCR using the following primers: c-myc, forward
primer 5′-acccttgccgcatccacgaaac-3′, reverse primer 5′-cgtagtcgagg-
tcatagttcctgttgg-3′; cyclin D1, forward primer 5′-ctgtttggcgtttccca-
gagtcatc, reverse primer 5′-agcctcctcctcacacctcctc-3′. For G6PDH, a
113-bp amplicon was generated (h-G6PDH Housekeeping Gene Set;
Roche, Mannheim, Germany). The calibrator cDNA was derived
from HCT116 cells and was used in serial dilutions simultaneously in
each run.
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Figure 1. Sulindac inhibits expression and nuclear accumulation of β-catenin in human colon cancer cells. (A, B) Sulindac treatment led to
down-regulation of β-catenin mRNA and protein expression in HCT116 cells and in the β-catenin knockout strains HAB-68mut and HAB-92wt
versus their solvent-treated counterparts (A). Ectopic CMV promoter–driven overexpression of S100A4 in stably transfected HCT116/S100A4
cells did not prevent β-catenin down-regulation by sulindac (B). Expression levels ofβ-cateninmRNAweremeasuredbyquantitative real- time
RT-PCR. Western blots for β-catenin were quantified by integrated density values by using the ChemiImager software (v5.5; Alpha Innotech
Corporation). (C) Nuclear accumulation ofβ-catenin,mainly observed inHCT116 andHAB-68mut cells, was decreasedafter sulindac treatment
(vs solvent-treated cells). Bars, 20 μm.
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Western Blot Analysis, Immunocytochemistry,
and Immunohistochemistry
Western blot analysis was performed as described previously [15]. We
used a polyclonal S100A4 antibody (Dako, Glostrup, Denmark), a
monoclonal β-catenin, and a monoclonal β-tubulin antibody (both BD
Biosciences, Heidelberg, Germany). Chemiluminescent reaction was
done with an enhanced chemiluminescence solution. Quantification of
the Western blots was performed by determining the integrated density
values using the ChemiImager software (v5.5; Alpha Innotech Corpora-
tion, San Leandro, CA). For immunocytochemistry, cells were cultured
on double-chamber slides (Nunc, Rochester, NY) and fixed, endoge-
nous peroxidase was inactivated, and membranes were permeabilized.
After blocking, cells were incubated with the β-catenin antibody. Detec-
tion was performed using the biotin-based ABC kit (Dako; antirabbit bi-
otin antibody, antibiotin-streptavidin-HRP) and diaminobenzidine as
substrate. For immunohistochemistry, incubations of the sections and
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detection procedure were done as for immunocytochemistry. Sections
were incubated with the β-catenin antibody or the S100A4 antibody.
S100A4 Gene Promoter Analysis
Electrophoretic mobility shift assay (EMSA) was performed as pre-
viously described using 3 μg of lysate, [15]. Briefly, we used biotin end-
labeled double-stranded oligonucleotides for the human S100A4
promoter (sense 5′-ccgggcatggggatccccaccccagtttttgtttctgaatctttatttt-
tttaagagaca-3′, antisense 5′-ggcccgtacccctaggggtggggtcaaaaacaaagact-
tagaaataaaaaaattctctgt-5′; BioTeZ) harboring the wild-type TCF
binding site. For chloramphenicol acetyltransferase (CAT)-ELISA,
the S100A4 promoter fragment pCAT-1097-TCFwt (−1097 to +33;
kindly provided by David Allard, University of Liverpool, Liverpool,
UK; [32]) was used. The plasmid pCAT3-Basic and transfections
without DNA served as controls. Transfer efficiency was controlled by
transfection of pCAT-Control (Clontech, Mountain View, CA). Trans-
fections and CAT-ELISA were carried out as described previously [15].
The amount of CAT protein was normalized to the protein content
of the respective lysate and expressed as picograms of CAT per milligram
of protein. Values are given as average of quadruplicates.
Cell Migration, Invasion, and Wound Healing
Cell migration was evaluated in transwell chambers, in which cells
need to pass a 12-μm pore membrane (Corning, Schiphol-Rijk, the
Netherlands). The number of migrated cells was counted after 24 hours.
For the invasion assays, Matrigel (1:2; BDBiosciences) was added to the
transwell membrane chambers 4 hours before seeding. Cells, which had
invaded through the Matrigel, were counted after 24 hours. Indepen-
dent migration and invasion assays were performed in triplicate [15].
For the scratch wound healing assay, wounds were created in confluent
cells by cell scraping using a pipette tip and were washed with the me-
dium to remove free-floating cells and debris. Wound healing within
the scrape line was documented daily until day 4 and repeated twice,
as described previously [33]. Scratch microphotographs were obtained
with a Leica-Leitz DMIL microscope and a Kappa CF 15/4 MCC-
MLUII Modul camera.
Colony Formation and Proliferation
For evaluation of cell growth in soft agar, cells were added to soft agar
(Invitrogen) supplemented with medium and 10% fetal calf serum.
Cells were grown in triplicate in soft agar cultures for 10 days, and col-
onies were counted in quadruplicate. For evaluation of in vitro growth,
cell numbers were determined in quadruplicate until day 5 using the
3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (Sigma,
Munich, Germany) colorimetric assay.
In Vivo Tumor Growth and Distant Metastasis after
Intrasplenic Transplantation
Intrasplenic transplantation of 5 × 106 HAB-92wt/mut cells or
HCT116/S100A4 cells was performed using 6- to 8-week-old nonobese
diabetic/severe combined immunodeficient mice (six mice per group)
[15]. Sulindac sulfide was administered daily by gavage. Treatment
was started at day 1 after cell transplantation and was finished the day
before the animals were killed. Dose finding was performed with 6.25,
12.5, 18, 25, and 50 mg/kg per day of sulindac. Control group animals
were treated with 10% Tween in saline (vehicle was used to solubilize
sulindac). Experiments were performed in accordance with the UK
Coordinating Committee on Cancer Research guidelines and approved
by the responsible local authorities (State Office of Health and Social
Affairs, Berlin, Germany). Mice were killed at day 19, and spleens (site
of tumor injection) and livers (metastasis target organ) were shock-
frozen in liquid nitrogen. To prove the effect of sulindac on β-catenin
and S100A4 expression in spleen tumors and liver metastases, serial
consecutive cryosections were made for immunohistochemistry and
for microdissection and subsequent RNA isolation. RNA quality was
proven (2100 Bioanalyzer; Agilent, Santa Clara, CA), and β-catenin
and S100A4 mRNA levels were determined by quantitative real-
time RT-PCR.
Statistical Analysis
Levels of statistical significance were evaluated by using the t-test or
the nonparametric two-sided Mann-Whitney rank sum test depending
on whether the data passed or failed a normal distribution test.
Results
Sulindac Inhibits Expression and Nuclear Accumulation
of β-catenin
We first evaluated the effect of sulindac on β-catenin expression. We
used a colon cancer model based on HCT116 cells, including the
β-catenin knockout strains HAB-68mut and HAB-92wt [15]. Levels of
β-catenin expression were dependent on the respective genotype, with
higher levels in heterozygous cells. Sulindac treatment resulted in down-
regulation of β-catenin mRNA and protein expression in all cell lines
analyzed when compared with their solvent-treated counterparts
(Figure 1A): inHCT116 cells, β-cateninmRNA expressionwas reduced
Figure 2. Sulindac inhibits transcriptional induction of S100A4by β-catenin in human colon cancer cells. (A) Sulindac treatment led to reduced
binding of β-catenin to the TCF/S100A4 promoter complex in HCT116 and HAB-68mut cells, the cell lines harboringmutant β-catenin. In HAB-
92wt cells that express exclusively wt β-catenin, no β-catenin/TCF/S100A4 promoter oligonucleotide complex formation was detectable.
EMSAwas performedwith 3 μg of lysate of solvent-treated or sulindac-treated cells andwith biotin end-labeled double-stranded oligonucleo-
tides for the humanS100A4promoter harboring thewild-type TCFbinding site. (B, C) CAT-ELISA. TheS100A4 promoter fragment pCAT-1097-
TCFwt (−1097 to+33)was cloned todrive the reporter geneexpressionCAT. TheplasmidpCAT3-Basic and transfectionswithoutDNAserved
as controls. The amount of CAT proteinwas normalized to the protein content of the respective lysate and expressed as picograms of CAT per
milligram of protein. Values are average of quadruplicates and are given as percentage of CAT expression in HCT116 cells (set as 100%).
Sulindac treatment led to down-regulation of S100A4promoter–mediated reporter geneexpressionwhencomparedwith their solvent-treated
counterparts (B). CMVpromoter–driven ectopic S100A4overexpression did not prevent down-regulation of S100A4promoter–driven reporter
gene expression by sulindac (C). (D, E) Sulindac treatment led to down-regulation of S100A4mRNA and protein expression in HCT116 cells, in
the β-catenin knockout strains HAB-68mut and HAB-92wt, and in the substrains with reconstituted heterozygous β-catenin genotype HAB-
68mut/wt and HAB-92wt/mut (vs their solvent-treated counterparts) (D). Ectopic CMV promoter–driven overexpression of S100A4 was not re-
sponsive to sulindac (E). Expression levels of S100A4mRNAweremeasured byquantitative real-timeRT-PCR.Western blots for S100A4were
quantified by integrated density values by using the ChemiImager software (v5.5; Alpha Innotech Corporation).
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to 53%, in the knockout strainsHAB-68mut andHAB-92wt to 59% and
69%, respectively (vs solvent-treated counterpart). On the basis of
measurements of the integrated density values, protein expression was
diminished to 64%, 57%, and 43% in HCT116, HAB-68mut, and
HAB-92wt cells, respectively (vs solvent-treated counterpart). Ectopic
cytomegalovirus (CMV) promoter-driven six-fold overexpression of
the β-catenin transcriptional target gene S100A4 did not prevent
β-catenin reduction by sulindac (Figure 1B). Nuclear accumulation of
β-catenin was preferentially observed in HCT116 and HAB-68mut cells
harboring mutant β-catenin. This nuclear β-catenin accumulation was
lost after treatment with sulindac (Figure 1C ). These findings are con-
sistent with previous reports [20–25].
Sulindac Inhibits Transcriptional Induction of S100A4
by β-Catenin
We previously identified the gene for the metastasis mediator
S100A4 as a transcriptional target gene of β-catenin and demonstrated
the direct dependence of S100A4 expression on β-catenin [15]. Because
sulindac affected the expression and nuclear localization of β-catenin,
we analyzed sulindac’s effects on the binding of β-catenin to the
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S100A4 promoter through the transcription factor TCF by EMSA. We
observed clear binding of β-catenin to the TCF/S100A4 promoter com-
plex in HCT116 and in HAB-68mut, the cell lines harboring mutant
β-catenin (Figure 2A). In HAB-92wt cells, which express exclusively
wild-type β-catenin, no β-catenin/TCF complex was detectable. Treat-
ment with sulindac led to reduction of β-catenin binding to the TCF/
S100A4 promoter complex inHCT116 andHAB-68mut cells. Thus, we
demonstrate that sulindac treatment results in the reduction of nuclear
accumulation of β-catenin, which is associated with a reduction in
β-catenin/TCF/S100A4 promoter oligonucleotide complex formation.
We then verified the effect of sulindac on S100A4 gene promoter ac-
tivity in cells transfected with a S100A4 promoter–driven CATreporter
construct. We observed high S100A4 promoter activity in cells harbor-
ing mutant β-catenin, either heterozygously or in the knockout strain
HAB-68mut. Sulindac treatment reduced S100A4 promoter–driven
reporter gene expression to 30% in HCT116 cells, to 21% and
32% in HAB-68mut and HAB-92wt cells, and to 56% and 32% in
HAB-68mut/wt and HAB-92wt/mut cells with the reconstituted hetero-
zygeous β-catenin genotype, respectively (vs solvent-treated counterpart;
Figure 2B). Concurrent expression of CMV promoter–driven S100A4
did not significantly affect the sulindac-induced down-regulation of
the S100A4 promoter–driven reporter gene expression (Figure 2C ).
Next, we directly analyzed the influence of sulindac on the expression
of the β-catenin target gene S100A4. Sulindac caused knockdown of
S100A4 mRNA expression, which ranged from 27% in HCT116 cells,
30% and 16% in the knockout strains HAB-68mut and HAB-92wt, to
25% and 54% inHAB-68mut/wt, andHAB-92wt/mut cells, respectively
(vs solvent-treated counterpart; Figure 2D). This was confirmed by
Western blots with reduced S100A4 protein in sulindac-treated cells,
as determined by measurements of the integrated density values. Pro-
tein expression was diminished to 51%, to 52%, to 59%, to 51%,
and to 37% in HCT116, HAB-68mut, HAB-92wt, HAB-68mut/wt,
and in HAB-92wt/mut cells, respectively (vs solvent-treated counter-
part). Ectopic overexpression of S100A4 was not inhibited by sulindac
(Figure 2E).
Sulindac-Induced Inhibition of Cell Migration and
Invasion by Interdicting S100A4
As we reported previously, migratory and invasive capabilities of these
cells directly depend on the β-catenin genotype and thereby, on S100A4
expression levels [15]. Here, we analyzed the effect of sulindac on mi-
gratory phenotypes and, correspondingly, on invasiveness. We observed
an inhibition of migration by sulindac in all cell lines, with a decrease to
46% in HCT116 cells, to 45% and 46% in the knockout strains, and
to 39% and 31% in HAB-68mut/wt and HAB-92wt/mut cells, respec-
tively (vs solvent-treated counterpart; Figure 3A). Cell invasion was
also decreased after sulindac treatment: to 31% in HCT116 cells, to
17% and 57% in the knockout strains, and to 28% and 23% in
HAB-68mut/wt and HAB-92wt/mut cells, respectively (vs solvent-
treated counterparts; Figure 3C ). Ectopic CMV promoter–driven
S100A4 overexpression was sufficient to rescue both inhibition of
migration and invasion caused by sulindac (85% and 101%of sulindac-
treated migrated and invaded cells compared with solvent-treated con-
trols, respectively, as illustrated in Figure 3, B and D).
Sulindac’s effects on cell motility were confirmed by a monolayer
scratch assay, which tracks the migration of cells into a wound area.
The situation at day 4 after injuring the cell monolayer is depicted (Fig-
ure 3E).Wound healing was dependent on β-catenin genotype and thus
on S100A4 expression. Cells with mutant β-catenin, and therefore with
high S100A4 levels, demonstrated accelerated wound healing compared
withHAB-92wt cells. However, sulindac treatment delayed wound heal-
ing in all cell lines analyzed. Again, ectopic overexpression of S100A4
largely prevented the sulindac-induced delay in directed cell motility.
Although the wound was not completely closed at this time point, a dif-
ference of the distance of the gap is seen in sulindac-treated HCT116/
S100A4 cells with respect to the sulindac-treated cell lines that are
not transfected with S100A4 (HCT116, HAB-68mut, HAB-92wt,
HAB-68mut/wt, and HAB-92wt/mut). The delay of wound closure
in the sulindac-treated HCT116/S100A4 cells when compared with
their solvent-treated counterparts may be partly explained by sulindac-
induced proliferation inhibition.
To validate our findings, we also treated additional human colon cancer
cell lines with sulindac: SW620 (harboring APC mutant, β- catenin wt),
LS174T (harboring APC wt, β-catenin mutant), and DLD1 (harboring
APCmutant, β-catenin wt), in addition to the HCT116 cells (harboring
APC wt, β-catenin mutant). The expression of S100A4 was detectable
in all cell lines analyzed (Figure W1A). We found sulindac-induced
reduction of S100A4 mRNA expression to 37%, to 25%, and to 28%
in SW620, LS174T, and DLD1 cells. We also tested the influence of
sulindac treatment on cell migration (Figure W1B). Thereby, we ob-
served a reduction of the number of migrating cells by treatment with
sulindac of 23%, 22%, and 38% in SW620, LS174T, and DLD1 cells.
Thus, the sulindac effect on S100A4 expression as well as on cell mi-
gration was verified in additional colon cancer cell lines.
We also analyzed the effect of sulindac on down-regulation of
additional β-catenin transcriptional target genes including c-myc and
Figure 3. Sulindac inhibits cell migration and invasion in human colon cancer cells. (A, B) Cell migration assay. Cell migration was evaluated
in transwell chambers with 12-μm pore membranes. The number of migrated cells was counted after 24 hours. Sulindac treatment led
to inhibition of cell migration in HCT116 cells, in the β-catenin knockout strains HAB-68mut and HAB-92wt, and in the substrains with rec-
onstituted heterozygous β-catenin genotype HAB-68mut/wt and HAB-92wt/mut (vs their solvent-treated counterparts) (A). Ectopic CMV
promoter–drivenS100A4overexpression preventedmigration inhibition by sulindac (B). (C, D) Cell invasion assay. Cell invasionwas evaluated
by adding Matrigel to the transwell chambers 4 hours before seeding. The number of invaded cells was counted after 24 hours. Sulindac
treatment led to inhibition of cell invasion migration in HCT116 cells, in the β-catenin knockout strains HAB-68mut and HAB-92wt, and in the
substrains with reconstituted heterozygous β-catenin genotype HAB-68mut/wt and HAB-92wt/mut (vs their solvent-treated counterparts) (C).
Ectopic CMVpromoter–driven S100A4 overexpression prevented invasion inhibition by sulindac (D). (E)Wound healing assay.Woundswere
created in confluent cells by cell scraping using a pipette tip and were washed with medium to remove free-floating cells and debris.Wound
healingwithin the scrape line was documented daily. Representative scrape lines are shown at day 4; dashed line indicates themargin of the
scratch at day 1. Bar, 200 μm. Wound healing was dependent on β-catenin genotype and thus on S100A4 expression. Cells with mutant
β-catenin, and therefore with high S100A4 levels, demonstrated accelerated wound healing compared with HAB-92wt cells. Sulindac treat-
ment led to inhibition of wound healing in all cell lines analyzed (vs their solvent-treated counterparts). Ectopic CMV promoter–driven S100A4
overexpression almost prevented the sulindac-induced delay in wound healing.
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cyclin D1. We found that sulindac treatment resulted in mRNA down-
regulation of c-myc and cyclin D1, as also observed for S100A4
(Table W1). We then transfected the CMV promoter–driven cDNA of
c-myc or cyclin D1 into HCT116 cells, treated them with sulindac (vs
solvent), and performed cell migration assays. We found that sulindac-
induced reduction of cell migration was only prevented in HCT116 cells
that ectopically overexpress S100A4. In HCT116/c-myc or HCT116/
cyclin D1 cells, no rescue of the sulindac-induced reduction in cell migra-
tion was observed (Table W2).
Sulindac-Induced Inhibition of Cell Proliferation and
Colony Formation
Next, we evaluated the effect of sulindac on cell proliferation abilities.
Adherent cell proliferation was measured for 5 days and was comparable
in all cell lines, except for a somewhat reduced proliferation rate of
HAB-92wt cells. Colony formation was enhanced in cells harboring
mutant β-catenin compared with HAB-92wt cells. Sulindac treatment
resulted in complete arrest of cell growth in all lines (Figure 4A). Treat-
ment with sulindac also inhibited anchorage-independent proliferation
in all cell lines: to 58% inHCT116 cells, to 46% and 76% in the knock-
out strains, and to 40% and 45% inHAB-68mut/wt andHAB-92wt/mut
cells, respectively (vs solvent-treated counterpart; Figure 4B). This in-
hibition of colony formation was not prevented by ectopic S100A4
overexpression. In contrast to the rescue abilities of S100A4 over-
expression on sulindac-induced inhibition of cell migration and inva-
sion, ectopic S100A4 overexpression did not rescue sulindac-induced
inhibition of adherent or anchorage-independent proliferation (Fig-
ure 4, A and C ).
Figure 4. Sulindac inhibits colony formation and proliferation in human colon cancer cells. (A) Proliferation assay. In vitro growth was eval-
uated by determining the cell numbers using the 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide colorimetric assay until day 5.
Adherent cell proliferationwas comparable in all cell lines, except for a slightly reducedproliferation rate ofHAB-92wt cells. Sulindac treatment
led to inhibition of cell proliferation in all cell lines analyzed (vs their solvent-treated counterparts). Ectopic CMV promoter–driven S100A4
overexpression did not prevent proliferation inhibition by sulindac. (B, C) Colony formation assay. For the evaluation of anchorage-independent
growth, cells were grown in soft agar for 10 days, and colonies were counted. Colony formation was enhanced in cells harboring mutant
β-catenin compared with HAB-92wt cells. Sulindac treatment led to inhibition of colony formation in all cell lines analyzed (vs their solvent-
treated counterparts) (B). Ectopic CMVpromoter–drivenS100A4overexpression did not prevent colony formation inhibition by sulindac (C).
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Antimetastatic Activity of Sulindac in Mice by Inhibition
of β-Catenin and S100A4 Expression
Next, we evaluated the effect of sulindac on in vivo metastasis. We
transplanted HAB-92wt/mut cells intrasplenically leading to tumor
growth in the spleen and to metastasis in the liver. Sulindac or sol-
vent was administered orally every day, starting 1 day after tumor
cell inoculation.
Dose finding experiments for sulindac were performed with 6.25,
12.5, 18, 25, and 50 mg/kg per day. We started these experiments with
a sulindac concentration of 50 mg/kg per day. Because we found this
concentration to be toxic, we lowered the concentration to 25 mg/kg
per day, which was also not well tolerated. Although reduced metastases
formation was observed in the animals treated with 50 and 25 mg/kg
per day of sulindac (vs solvent-treated animals), these results were
not considered owing to partial toxicity. On the other side, sulindac
was very well tolerated but ineffective at concentrations of 12.5 and
6.25 mg/kg per day with respect to metastasis reduction.
However, sulindac at nontoxic concentrations, for example, 18mg/kg
per day, significantly reduced tumor growth as well as metastasis forma-
tion in vivo, compared with solvent-treated control animals (Figure 5A).
This demonstrates the narrow concentration range where sulindac
is nontoxic but effective with respect to metastasis inhibition. Tumor
growth in the spleen was inhibited by sulindac to approximately 43%.
Mean tumor weights with and without sulindac were 181 and 418 mg,
respectively (P = .014; Figure 5B). We also investigated the effect of
sulindac on the liver metastasis rate in mice. Metastases per animal were
reduced by sulindac to approximately 37% of the solvent control. Mean
numbers of metastases per animal with and without sulindac were 6.0
and 15.85, respectively (P = .025; Figure 5C). Body weights of the mice
were unaffected by sulindac, but one of six mice treated with sulindac
died of unknown reasons.
To assess the effect of sulindac treatment on molecular targets in vivo,
we determined the levels of β-catenin and S100A4 in the spleen tumors
and in the liver metastases of sulindac- and solvent-treated mice.We de-
tected significantly reduced expressions of β-catenin (P = .0221) and
S100A4 (P = .004) in the spleen tumors of sulindac-treated animals
compared with solvent-treated animals at the mRNA level (Figure 6,
A and C ). However, the differences of the β-catenin and S100A4
mRNA expressions in the liver metastases of solvent- and of sulindac-
treated mice did not reach statistical significance (Figure 6, A and C ;
β-catenin mRNA in liver metastases: median solvent-treated, 11.075;
median sulindac-treated, 0.628; S100A4 mRNA: median solvent-
treated, 63.49; median sulindac-treated, 7.945). At the protein level,
diminished β-catenin as well as S100A4 protein expressions were
Figure 5. Sulindac inhibits tumor growth and metastasis in human colon cancer xenografts in mice. Intrasplenic transplantation of 5 × 106
HAB-92wt/mut cells was performed using NOD/SCID mice. This led to tumor growth in the spleen and to liver metastases. Sulindac treat-
ment was started at day 1 after intrasplenic transplantation, was administered daily by gavage (18 mg/kg per day), and was finished the day
before the animals were killed. Mice were killed at day 19, and spleens (site of tumor injection) and livers (metastasis target organ) were
shock-frozen in liquid nitrogen. Control group animals were treated with 10% Tween in saline (vehicle was used to solubilize sulindac). (A)
Tumors in the spleens and metastases in the livers are shown (one representative mouse per group). Sulindac treatment resulted in the
reduction of splenic tumor growth and of liver metastasis (vs the solvent-treated control mice). (B, C) Sulindac treatment resulted in signifi-
cantly reduced tumor weight in the spleen (P = .014) (B) and in significantly reduced numbers of liver metastases (P = .025) (C) compared
with solvent-treated control animals. (D) Body weight of mice was not influenced by sulindac.
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observed by immunohistochemistry in the tumors as well as in the liver
metastases of the sulindac-treated animals (Figure 6, B and D).
To evaluate the effect of ectopic overexpression of S100A4 on
sulindac-induced reduction of tumor growth and liver metastasis,
we transplanted HCT116/S100A4 cells intrasplenically and adminis-
tered sulindac daily (Figure 7A). Neither tumor growth in the spleen
(P = .679) nor liver metastasis (P = .658) were reduced by sulindac
when using cells ectopically overexpressing S100A4 (Figure 7, B
and C ). Body weight was also unaffected by treatment with sulindac
(Figure 7D).We also analyzed the effect of sulindac on S100A4 protein
levels by immunohistochemistry. In contrast to the sulindac-induced
reduction of S100A4 protein in tumors and metastases originating
Figure 6. Sulindac inhibits β-catenin and S100A4 gene expression in spleen tumors and liver metastases in mice. The effect of sulindac
treatment (vs solvent treatment) on β-catenin and S100A4 mRNA expressions in the spleen tumors and liver metastases was evaluated
by using serial consecutive cryosections for microdissection, subsequent RNA isolation, and quantitative real-time RT-PCR. The protein ex-
pression of β-catenin and S100A4was determined by immunohistochemistry. (A, B) Sulindac treatment (18mg/kg per day) resulted in down-
regulation of β-catenin mRNA expression in spleen tumors (P= .021) and in liver metastases compared with solvent-treated control animals
(A). Representative cryosections of spleen tumors and liver metastases also showed down-regulation of β-catenin protein expression after
sulindac treatment (vs solvent-treated control animals) (B). Bars, 20 μm. (C, D) Sulindac treatment resulted in significant down- regulation of
S100A4mRNA expression in spleen tumors (P= .004) and in liver metastases compared with solvent-treated control animals (C). Represen-
tative cryosections of spleen tumors and liver metastases also showed down-regulation of S100A4 protein expression after sulindac treat-
ment (vs solvent-treated control animals) (D). Bars, 20 μm.
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Figure 7. Ectopic CMV promoter–driven S100A4 overexpression prevents inhibition of tumor growth and metastasis in human colon
cancer xenografts in mice by sulindac. To evaluate the effect of ectopic CMV promoter–driven overexpression of S100A4 on sulindac-
induced reduction of tumor growth and liver metastasis, intrasplenic transplantation of 5 × 106 HCT116/S100A4 cells was performed
using NOD/SCID mice. This led to tumor growth in the spleen as site of transplantation and to liver metastases. Sulindac treatment was
started at day 1 after intrasplenic transplantation, was administered daily by gavage (18 mg/kg per day), and was finished the day before
the animals were killed. Mice were killed at day 19, and spleens (site of tumor injection) and livers (metastasis target organ) were shock-
frozen in liquid nitrogen. Control group animals were treated with 10% Tween in saline (vehicle was used to solubilize sulindac). (A)
Tumors in the spleens and metastases in the livers are shown (one representative mouse per group). Sulindac treatment had no effect
on tumor growth or liver metastasis. (B, C) Neither tumor growth (B) nor liver metastasis (C) was reduced by sulindac (vs solvent-treated
control animals) when transplanting cells ectopically overexpressing CMV promoter–driven S100A4. Body weight of mice was not in-
fluenced by sulindac (D). (E) Sulindac treatment did not alter the S100A4 protein expression in ectopically S100A4-overexpressing
HCT116/S100A4 cells (vs solvent-treated control animals). Representative cryosections of spleen tumors and liver metastases are
shown. Bars, 20 μm.
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fromHAB-92wt/mut cells, sulindac treatment did not alter the S100A4
protein expression in ectopically S100A4-overexpressing HCT116/
S100A4 cells (vs solvent-treated control animals; Figure 7E).
Discussion
Here we report the antimetastatic activity of sulindac. We demonstrate
the mechanism of sulindac action, which involves intervening in
β-catenin signaling and thus interdicting S100A4. Rescue of the meta-
static phenotype by ectopic S100A4 provides a clear indication that this
protein plays a key role in the process. Although this does not mean that
other β-catenin–regulated genes do not also play important roles, the
association of down-regulation of S100A4 in tumors treated in vivo
with inhibition of metastasis and the lack of response of tumors express-
ing ectopic S100A4 support a critical role for this protein in Wnt/β-
catenin–driven metastasis.
Sulindac has beenwell established as a colon cancer–chemopreventive
agent [34,35]. It has pleiotropic activities as a cyclooxygenase (COX)
inhibitor and as an inhibitor of polyamine biosynthesis. This latter
activity provided the rationale for its combination with difluoromethy-
lornithine in a large-scale trial for chemoprevention of sporadic colo-
rectal adenomas [36,37]. This combination trial produced a striking
preventative effect in the sulindac/difluoromethylornithine arm [38].
It is less well known that pharmacological manipulation with sulin-
dac negatively regulates Wnt/β-catenin signaling, although NSAIDs
have been repeatedly evaluated as potential Wnt/β-catenin pathway
therapeutics [39]. Sulindac acts through inhibition of β-catenin expres-
sion and nuclear accumulation and by enhanced β-catenin degradation
[21–25]. Traditional NSAIDs, including sulindac, inhibit COX result-
ing in reducedWnt-signaling by induced β-catenin degradation, partic-
ularly in colon cancer [40].
We have previously shown that β-catenin regulates S100A4 expres-
sion transcriptionally and that mutant β-catenin acts in a dominant
fashion. β-Catenin–induced cell migration and invasion was dependent
on S100A4 and was abrogated by small interfering RNA acting on
S100A4. These findings demonstrated that S100A4 is essential for
increased cell motility initiated by β-catenin/TCF signaling [15].
The importance of S100A4 as a metastasis-inducing protein in vivo
has been reported in several studies. Transgenic mouse models over-
expressing S100A4 showed enhanced metastatic activity [41,42].
S100A4-deficient mice demonstrated suppression of tumor develop-
ment and metastasis formation even when injected with highly
metastatic mouse mammary carcinoma cells [43]. The S100A4 gene
functions as a pleiotropic mediator of metastasis with intracellular
actions affecting motility, secretion of metalloproteases, and invasion.
S100A4 promotes the metastatic cascade by increasing cellular motility
through interaction with cytoskeletal proteins. It coaggregates with actin
filaments, binds to nonmuscle tropomyosin, and interacts with non-
muscle myosin II. S100A4 causes a migratory phenotype bymodulating
cell adhesion through binding liprin β1 or p53, thereby affecting p53-
mediated migration and invasion rates particularly in colon cancer cell
lines. Beside its intracellular interactions, S100A4 is released to the
extracellular space and promotes metastasis formation and angiogenesis
in vivo (reviewed in references [5–7]). Metastatic phenotypes were re-
duced by experimental interventions that prevent S100A4 protein
production, using S100A4 antisense oligonucleotides, anti–S100A4 ri-
bozymes, or S100A4-RNAi [15,44–46]. Our approach aims at the
pharmacologic inhibition of S100A4 expression as a strategy for metas-
tasis prevention. On the basis of our signaling data and on sulindac
actions on β-catenin, we hypothesized a reduction or prevention of
metastasis by sulindac, mediated through β-catenin and its target gene
S100A4. Indeed, we demonstrated sulindac-induced down-regulation
of β-catenin in vitro and in vivo and reduced nuclear accumulation in
cell culture. We had already shown that β-catenin binds to the S100A4
gene promoter through a TCF site [15]. Here, we provide evidence that
this binding of β-catenin to the S100A4 promoter through TCF is di-
minished by sulindac, leading not only to lowered reporter expression
but also to reduced expression of the metastasis mediator S100A4 itself.
These findings underline the importance of S100A4 as transcriptional
β-catenin target gene and, moreover, point to possible metastasis inter-
vention strategies through β-catenin/TCF signaling.
Sulindac also knocked down functional parameters such as β-catenin–
induced migratory and invasive capacities. In this context, we are aware
of the complexity of sulindac actions and of the Wnt/β-catenin signal-
ing pathway. For instance, the anti-invasive activity of sulindac was also
regulated by ATF3 in colon cancer cells [47]. Therefore, we tested the
effect of sulindac with respect to the inhibition of S100A4 expression
and cell migration in additional colon cancer cell lines. Although these
cell lines differ in their mutation status concerning APC and β-catenin,
sulindac did reduce S100A4 expression as well as the migratory abili-
ties of these lines. Furthermore, ectopic overexpression of S100A4, but
not of c-myc or cyclin D1, rescued migration and invasion, making
these functional sulindac effects dependent on the action of S100A4
[48]. In addition to S100A4, other β-catenin target genes may con-
tribute to cell motility inhibition by sulindac. However, the ectopic
overexpression of S100A4 was sufficient to completely overcome the
anti-invasive effect of sulindac. Thus, we suggest a crucial role for
S100A4 in the context of sulindac-induced reduction of cell motility.
Although ectopic overexpression of S100A4 also accelerated directed
migration in the wound healing assay, the closing of the wound was not
complete in sulindac-treated HCT116/S100A4 cells when compared
with their solvent-treated counterpart. This might be due to the
sulindac-induced reduction of cell proliferation that was not rescued
by ectopic overexpression of S100A4. Other β-catenin target genes
that were downregulated after sulindac treatment might contribute
to proliferation inhibition. Furthermore, antiproliferative activity of
sulindac in colon cancer cells was previously reported to be mediated
through the Csk/Src axis [49].
Finally, we transplanted colon cancer cells with gain-of-function β-
catenin and high S100A4 expression into mice and observed tumor
growth and liver metastasis. Sulindac treatment resulted in significantly
decreased splenic tumor growth and metastasis formation. Inhibition of
tumorigenesis by sulindac has been well described [24,50]. In this re-
port, the formation of experimental liver metastases in mice was signifi-
cantly knocked down by sulindac, providing proof of principle for
antimetastatic activity. Reduction in tumor growth and metastasis
was accompanied by sulindac-induced knockdown of both β-catenin
and S100A4 expression in these tissues, thereby confirming our initial
hypothesis. Antimetastatic effects of sulindac were not observed, when
using a cell line model with high ectopic overexpression of S100A4 for
in vivo transplantation, illustrating the key importance of the S100A4
promoter in sulindac action.
Thus, we demonstrate here the activity of sulindac as an antimeta-
static compound and show that the mechanism involves intervening
in the β-catenin-S100A4 cellular program for colon cancer. Targeting
S100A4 is a very promising approach for cancer therapy [51,52]. Other
inhibitors targeting theWnt/β-catenin pathway may also offer potential
as antimetastatic agents by interdicting the expression of target genes
such as S100A4. Small molecule inhibitors have been identified by
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high-throughput screening that are able to disrupt the β-catenin/TCF
interaction and block growth of colon cancer cell lines [53–55]. Other
inhibitors like silibinin also decreased β-catenin expression resulting in
down-regulation of its target genes cyclin D1 and c-myc and inhibition of
tumorigenesis [56]. It has also been taken into account that other signal-
ing cascades besides the Wnt/β-catenin pathway might influence
S100A4 expression; for instance, ErbB2 activates S100A4 expression
in medulloblastoma cell lines during EMT through the Ras/Raf/Mek/
Erk1/2 signaling pathways [32]. S100A4 expression induction by α6β4
integrin through NFAT5 transcription factor was reported in breast
cancer cell lines [57]. Recently, transcriptional regulation of S100A4
under hypoxic conditions was shown in a gastric cancer cell line [58].
Therefore, pathway-based intervention strategies should consider tissue-
specific transcriptional regulation of S100A4.
In summary, we demonstrate here the antimetastatic activity of sulin-
dac for restriction of colon cancer metastasis in mice. Sulindac acts
through intervening in β-catenin signaling and interdicting expression
of the metastasis mediator S100A4, a β-catenin target gene. Because
ectopic S100A4 rescues motility abilities in vitro and themetastatic phe-
notype in mice, S100A4 plays a crucial role in the Wnt/β-catenin–
driven metastatic process, despite other important β-catenin–regulated
genes. This is also demonstrated by downregulated S100A4 expression
in tumors and metastases of sulindac-treated mice that show inhibition
of metastasis formation. Indeed, down-regulation of S100A4 expression
in tumor tissue may provide a useful pharmacodynamic marker for
potential clinical trials of sulindac or other Wnt/β-catenin inhibitors
as antimetastatic agents. As mentioned above, S100A4 was previously
shown to function as a prognostic indicator for the identification of pa-
tients at high risk for developing metastases metachronously and un-
favorable survival prognosis. Thus, intervention strategies targeting
key molecules of the Wnt/β-catenin pathway may represent promis-
ing approaches to inhibit metastasis formation especially when induced
by S100A4. This new insight into the antimetastatic activity of sulindac
could serve as the basis for chemoprevention of metastasis in individ-
ual colon cancer patients with high S100A4 expression and high risk
for metastasis.
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Table W1. Sulindac-Induced Reduction of mRNA Expression of β-Catenin Target Genes S100A4,
c-myc, and cyclin D1 in HCT116 Cells, in the β-Catenin Knockout Strains HAB-68mut and HAB-
92wt, and in the Sublines with Reconstituted Heterozygous β-Catenin Genotype HAB-68mut/wt and
HAB-92wt/mut.
β-Catenin
Target Gene
HCT116 HAB-68mut HAB-92wt HAB-68mut/wt HAB-92wt/mut
% Solvent-Treated Cells
S100A4 28.01 30.12 16.89 25.91 54.94
c-myc 74.91 52.99 72.99 54.03 60.00
cyclin D1 52.46 44.17 69.93 55.44 74.19
Values are given as percentages of the mRNA expression of the respective β-catenin target gene in
sulindac-treated cells versus their solvent-treated counterpart.
Figure W1. Sulindac inhibitsS100A4expression andcellmigration in
the human colon cancer cells SW620, LS174T, and DLD1. (A) Sulin-
dac treatment led todown-regulation of S100A4mRNAexpression in
SW620, LS174T, and DLD1 cells (vs their solvent-treated counter-
parts). Expression levels of S100A4mRNAweremeasuredbyquanti-
tative real-timeRT-PCR. (B) Sulindac treatment led to inhibition of cell
migration in SW620, LS174T, andDLD1cells (vs their solvent- treated
counterparts). Cell migration was evaluated in transwell chambers
with 12-μm pore membranes. The number of migrated cells was
counted after 24 hours.
Table W2. Ectopic Overexpression of S100A4, But Not of Ectopic c-myc and cyclin D1, Prevents
Sulindac-induced Reduction of Cell Migration of HCT116 Cells.
HCT116/β-Catenin
Target Gene
No. Migrated Sulindac-Treated Cells, % Solvent-
Treated Cells
HCT116 46.78 <.001
HCT116/S100A4 85.11 NS (P = .212)
HCT116/c-myc 54.62 .002
HCT116/cyclin D1 37.85 <.001
Values are given as percentages of the number of migrated cells in sulindac-treatedHCT116, HCT116/
S100A4, HCT116/c-myc, and HCT116/cyclin D1 cells versus their solvent-treated counterparts.
NS indicates not significant.
